ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01392521
Recruitment Status : Completed
First Posted : July 12, 2011
Last Update Posted : April 17, 2015
Sponsor:
Information provided by (Responsible Party):
Bayer

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : February 2014
  Actual Study Completion Date : April 2014